OC.02.5 EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF SWITCHING FROM ORIGINATOR INFILIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN A LARGE COHORT OF IBD PATIENTS. (1st October 2020) - Privitera, G.; Pugliese, D.; Tolusso, B.; Gremese, E.; Papa, A.; Papparella, L.G.; Gasbarrini, A.; Rapaccini, G.L.; Guidi, L.; Armuzzi, A.